|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US7090843B1
(en)
†
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US20050123536A1
(en)
*
|
2001-11-20 |
2005-06-09 |
Che-Leung Law |
Treatment of immunological disorders using anti-dc30 antibodies
|
|
JP2005517674A
(ja)
*
|
2002-01-03 |
2005-06-16 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー |
腫瘍の処置に有用な新規免疫コンジュゲート
|
|
EP1471938A4
(en)
|
2002-01-09 |
2008-03-05 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
PT2357006E
(pt)
*
|
2002-07-31 |
2016-01-22 |
Seattle Genetics Inc |
Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
|
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
AU2005292227A1
(en)
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating CD30 positive lymphomas
|
|
ES2498794T3
(es)
|
2005-02-18 |
2014-09-25 |
Medarex, L.L.C. |
Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
|
US8257706B2
(en)
*
|
2006-08-25 |
2012-09-04 |
Seattle Genetics, Inc. |
CD30 binding agents and uses thereof
|
|
AR067543A1
(es)
|
2007-07-16 |
2009-10-14 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
|
CN106432496B
(zh)
|
2007-07-16 |
2020-02-07 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
|
WO2009026274A1
(en)
|
2007-08-22 |
2009-02-26 |
Medarex, Inc. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
|
AU2008310908B2
(en)
|
2007-10-12 |
2014-01-09 |
Seagen Inc. |
Combination therapy with antibody-drug conjugates
|
|
EP2247620B1
(en)
|
2008-01-31 |
2016-05-18 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
PT2326350E
(pt)
|
2008-09-08 |
2013-12-10 |
Psma Dev Company L L C |
Compostos para matar células cancerosas resistentes a taxano, que expressam psma
|
|
CA3150199C
(en)
|
2009-01-09 |
2025-07-22 |
Seagen Inc. |
WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE
|
|
KR101224468B1
(ko)
*
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US9272052B2
(en)
|
2010-10-22 |
2016-03-01 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
AU2013251541B2
(en)
*
|
2012-04-27 |
2018-01-25 |
Amgen Inc. |
Human CD30 ligand antigen binding proteins
|
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
|
IL302494B2
(en)
|
2012-10-11 |
2024-11-01 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugates and methods for their preparation
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
AU2013364065B2
(en)
|
2012-12-21 |
2018-10-04 |
Altrubio Inc. |
Hydrophilic self-immolative linkers and conjugates thereof
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
PT2968588T
(pt)
|
2013-03-15 |
2019-05-08 |
Abbvie Inc |
Formulações de conjugado de fármaco-anticorpo anti-egfr
|
|
KR20150132864A
(ko)
|
2013-03-15 |
2015-11-26 |
애브비 인코포레이티드 |
항체 약물 접합체(adc) 정제
|
|
WO2014169078A2
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
AU2014283185B2
(en)
|
2013-06-21 |
2019-05-02 |
Araris Biotech Ltd. |
Enzymatic conjugation of polypeptides
|
|
KR102538993B1
(ko)
|
2013-10-15 |
2023-06-02 |
씨젠 인크. |
개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
|
|
WO2015113476A1
(zh)
|
2014-01-29 |
2015-08-06 |
上海恒瑞医药有限公司 |
配体-细胞毒性药物偶联物、其制备方法及其应用
|
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2952876A1
(en)
|
2014-06-20 |
2015-12-23 |
Bioalliance C.V. |
Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
|
|
AU2015282627B2
(en)
|
2014-06-30 |
2020-04-02 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107849096B
(zh)
|
2015-05-30 |
2022-05-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
CN107847481A
(zh)
|
2015-06-03 |
2018-03-27 |
波士顿生物医药有限公司 |
包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂
|
|
CN112125929A
(zh)
|
2015-06-15 |
2020-12-25 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
EP3380620B1
(en)
|
2015-11-23 |
2024-07-03 |
Novartis AG |
Optimized lentiviral transfer vectors and uses thereof
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
TWI753875B
(zh)
|
2016-01-08 |
2022-02-01 |
美商美國全心醫藥生技股份有限公司 |
四價抗psgl-1抗體及其用途
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
US11464869B2
(en)
|
2016-11-14 |
2022-10-11 |
Takeda Pharmaceutical Company Limited |
Non-adult human dosing of brentuximab vedotin
|
|
CA3045306A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
がんを処置するための方法
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
AU2018347406B2
(en)
|
2017-10-11 |
2025-09-04 |
Seagen Inc. |
Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
AU2018355427A1
(en)
|
2017-10-25 |
2020-04-30 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
MX2020004563A
(es)
|
2017-11-01 |
2020-08-13 |
Seattle Genetics Inc |
Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.
|
|
CN110305211A
(zh)
|
2018-03-20 |
2019-10-08 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3155291A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
MX2021003734A
(es)
|
2018-10-01 |
2021-07-16 |
Seagen Inc |
Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
|
|
CN113056288A
(zh)
|
2018-11-20 |
2021-06-29 |
康奈尔大学 |
放射性核素的大环配合物及其在癌症的放射治疗中的应用
|
|
US20240245670A1
(en)
|
2018-12-20 |
2024-07-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
AU2020347715A1
(en)
|
2019-09-18 |
2022-04-07 |
Systimmune, Inc. |
Camptothecin derivative and conjugate thereof
|
|
CA3155341A1
(en)
|
2019-09-25 |
2021-04-01 |
Seagen Inc. |
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
CA3152316A1
(en)
|
2019-10-04 |
2021-04-08 |
Scott C. Jeffrey |
Camptothecin peptide conjugates
|
|
EP4054647A1
(en)
|
2019-11-04 |
2022-09-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
|
KR20220116522A
(ko)
|
2019-12-20 |
2022-08-23 |
노파르티스 아게 |
증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
|
|
BR112022014398A2
(pt)
|
2020-01-22 |
2022-09-13 |
Shanghai Senhui Medicine Co Ltd |
Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina
|
|
EP4096713A1
(en)
|
2020-01-31 |
2022-12-07 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
|
CA3175733A1
(en)
|
2020-03-25 |
2021-09-30 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Pharmaceutical composition comprising antibody drug conjugate and use thereof
|
|
CA3175048A1
(en)
|
2020-03-25 |
2021-09-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Preparation method for antibody medicament conjugate
|
|
MX2022012621A
(es)
|
2020-04-10 |
2023-01-18 |
Seagen Inc |
Enlazadores de variantes de carga.
|
|
IL298155A
(en)
|
2020-05-13 |
2023-01-01 |
Seagen Inc |
Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
AU2022208054A1
(en)
|
2021-01-15 |
2023-07-27 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
US12036286B2
(en)
|
2021-03-18 |
2024-07-16 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20230171980A
(ko)
|
2021-04-20 |
2023-12-21 |
씨젠 인크. |
항체 의존성 세포 독성의 조절
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
AU2022283467A1
(en)
|
2021-05-28 |
2023-12-07 |
Seagen Inc. |
Anthracycline antibody conjugates
|
|
CN118451108A
(zh)
|
2021-10-29 |
2024-08-06 |
思进公司 |
用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
CN114891101B
(zh)
*
|
2021-12-02 |
2023-06-16 |
吉林省农业科学院 |
一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
|
|
KR20250004952A
(ko)
|
2022-03-17 |
2025-01-08 |
씨젠 인크. |
캄프토테신 접합체
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CA3252067A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory Antibody-Drug Conjugates
|
|
TW202430550A
(zh)
|
2022-10-18 |
2024-08-01 |
日商明治製菓藥業股份有限公司 |
T細胞性腫瘤之治療劑
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
WO2024197151A2
(en)
|
2023-03-22 |
2024-09-26 |
Salubris Biotherapeutics, Inc. |
Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
TW202535940A
(zh)
|
2023-10-24 |
2025-09-16 |
美商思進公司 |
化學治療化合物及使用方法
|
|
WO2025096626A1
(en)
|
2023-10-31 |
2025-05-08 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025169056A1
(en)
|
2024-02-06 |
2025-08-14 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
CN119331093B
(zh)
*
|
2024-11-04 |
2025-07-11 |
武汉伊莱瑞特生物科技股份有限公司 |
一种抗CD30的兔源Fab抗体及其制备方法和应用
|